View : 66 Download: 0

Epigenetics in non-alcoholic fatty liver disease

Title
Epigenetics in non-alcoholic fatty liver disease
Authors
Lee, JoohoKim, YuriFriso, SimonettaChoi, Sang-Woon
Ewha Authors
김유리
SCOPUS Author ID
김유리scopus
Issue Date
2017
Journal Title
MOLECULAR ASPECTS OF MEDICINE
ISSN
0098-2997JCR Link1872-9452JCR Link
Citation
vol. 54, pp. 78 - 88
Keywords
EpigeneticsNon-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)DNA methylationHistone modificationsmicroRNA
Publisher
ELSEVIER SCIENCE BV
Indexed
SCIE; SCOPUS WOS scopus
Abstract
Non-alcoholic fatty liver disease (NAFLD), a common hepatic disorder ranging from simple steatosis through steatohepatitis to fibrosis and cirrhosis, is an emerging health concern. NAFLD is a pathologic condition characterizedby the buildup of extra fat in liver cells that is not caused by alcohol consumption. Excess hepatic fat accumulation results from increased delivery of triglycerides (TG) to the liver or conversion of surplus carbohydrates to TG. Importantly, a subgroup of NAFLD results in hepatocellular injury and inflammation, which is referred to as non-alcoholic steatohepatitis (NASH), and may progress to irreversible cirrhosis and hepatocellular carcinoma (HCC). NAFLD shares, in part, the common pathogenesis of metabolic syndrome including obesity, hyperlipidemia, insulin resistance, mitochondrial damage, oxidative stress response, and the release of inflammatory cytokines. Epigenetics, an inheritable phenomenon that affects gene expression without altering the DNA sequence, provides a new perspective on the pathogenesis of NAFLD. Reversible epigenetic changes take place at the transcriptional level and provide a phenotypic connection between the host and environment. An accumulating body of evidence suggests the importance of epigenetic roles in NAFLD, which in turn can be identified as potential therapeutic targets and non-invasive biomarkers of NAFLD. It is anticipated that the epigenetic modifiers in NAFLD may provide novel molecular indicators that can determine not only the initial risk but also the disease progression and prognosis. In the present review, we update the roles of epigenetics as pathologic mechanisms, therapeutic targets and biomarkers in NAFLD. (C) 2016 Elsevier Ltd. All rights reserved.
DOI
10.1016/j.mam.2016.11.008
Appears in Collections:
신산업융합대학 > 식품영양학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE